Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
Dalila Costa(Hospital Braga), Thomas Reiberger(Harvard University), Benedikt Simbrunner(Austrian Academy of Sciences), Lukas Hartl(Medical University of Vienna), Philipp Schwabl(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Harvard University), Rafael Paternostro(Medical University of Vienna), Albert Friedrich Stättermayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Michael Trauner(Medical University of Graz), David Bauer(Austrian Academy of Sciences)
Cited by 202
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287